SG Americas Securities LLC Acquires 348,743 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)

SG Americas Securities LLC lifted its holdings in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) by 2,004.2% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 366,144 shares of the company’s stock after buying an additional 348,743 shares during the period. SG Americas Securities LLC’s holdings in Apellis Pharmaceuticals were worth $8,008,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of the business. EverSource Wealth Advisors LLC lifted its stake in Apellis Pharmaceuticals by 2,707.1% during the 4th quarter. EverSource Wealth Advisors LLC now owns 786 shares of the company’s stock valued at $25,000 after acquiring an additional 758 shares during the period. Signaturefd LLC grew its stake in shares of Apellis Pharmaceuticals by 357.2% in the fourth quarter. Signaturefd LLC now owns 1,175 shares of the company’s stock worth $37,000 after acquiring an additional 918 shares during the period. GF Fund Management CO. LTD. purchased a new position in shares of Apellis Pharmaceuticals during the fourth quarter valued at approximately $83,000. US Bancorp DE raised its holdings in shares of Apellis Pharmaceuticals by 70.0% during the fourth quarter. US Bancorp DE now owns 3,223 shares of the company’s stock valued at $103,000 after purchasing an additional 1,327 shares during the last quarter. Finally, Covestor Ltd lifted its position in Apellis Pharmaceuticals by 1,819.2% during the fourth quarter. Covestor Ltd now owns 3,992 shares of the company’s stock valued at $127,000 after purchasing an additional 3,784 shares during the period. 96.29% of the stock is currently owned by institutional investors.

Apellis Pharmaceuticals Stock Performance

Shares of APLS opened at $19.27 on Thursday. The company has a quick ratio of 3.73, a current ratio of 4.36 and a debt-to-equity ratio of 1.91. The business has a 50-day simple moving average of $18.32 and a two-hundred day simple moving average of $25.44. The stock has a market cap of $2.42 billion, a price-to-earnings ratio of -9.49 and a beta of 0.68. Apellis Pharmaceuticals, Inc. has a 52 week low of $16.10 and a 52 week high of $43.76.

Apellis Pharmaceuticals (NASDAQ:APLS) last issued its quarterly earnings results on Wednesday, May 7th. The company reported ($0.74) EPS for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.38). The company had revenue of $149.90 million during the quarter, compared to analysts’ expectations of $197.61 million. Apellis Pharmaceuticals had a negative return on equity of 103.11% and a negative net margin of 34.97%. The business’s quarterly revenue was down 3.2% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.54) EPS. On average, analysts expect that Apellis Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on APLS. Needham & Company LLC dropped their price target on Apellis Pharmaceuticals from $40.00 to $29.00 and set a “buy” rating on the stock in a research note on Wednesday, May 7th. HC Wainwright reiterated a “buy” rating and set a $57.00 price objective on shares of Apellis Pharmaceuticals in a research report on Monday, March 3rd. JPMorgan Chase & Co. upped their price objective on Apellis Pharmaceuticals from $50.00 to $54.00 and gave the company an “overweight” rating in a research report on Tuesday, March 4th. Wells Fargo & Company upped their price objective on Apellis Pharmaceuticals from $26.00 to $29.00 and gave the company an “equal weight” rating in a research report on Monday, June 2nd. Finally, Scotiabank reduced their price objective on Apellis Pharmaceuticals from $28.00 to $20.00 and set a “sector perform” rating for the company in a research report on Thursday, May 8th. Nine investment analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Apellis Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $40.05.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).